Welcome to our dedicated page for PowerUp Acquisition news (Ticker: PWUP), a resource for investors and traders seeking the latest updates and insights on PowerUp Acquisition stock.
The news feed for PowerUp Acquisition Corp. (PWUP) captures the company’s evolution as a special purpose acquisition company and its role in taking biopharmaceutical businesses public. Public announcements trace PWUP’s path from its formation as a blank check company through multiple transaction processes, including agreements with Visiox Pharmaceuticals, Inc. and Aspire Biopharma, Inc.
News items include disclosures about the execution of definitive business combination agreements, the filing of registration statements on Form S-4 with the U.S. Securities and Exchange Commission, and shareholder meeting notices related to extending the deadline for completing an initial business combination. Releases also cover Nasdaq listing matters, such as a notice regarding a late Form 10-Q filing and the company’s subsequent steps to regain compliance.
A significant portion of the coverage focuses on the completed business combination between PowerUp Acquisition Corp. and Aspire Biopharma, Inc., described as creating Aspire Biopharma Holdings, Inc., a Nasdaq-listed biopharmaceutical company. These articles outline Aspire Biopharma’s focus on novel delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements, and describe the expected trading of the combined company’s common stock and warrants under the symbols ASBP and ASBPW.
By following PWUP-related news, readers can review the historical sequence of transaction announcements, regulatory milestones, shareholder votes, and listing developments that led from PowerUp’s SPAC structure to the creation of a publicly traded biopharmaceutical company. This page serves as an organized record of company communications and market updates linked to the PWUP ticker.
Aspire Biopharma Holdings has completed its business combination with PowerUp Acquisition Corp, creating a Nasdaq-listed biopharmaceutical company. The company will trade under the ticker symbol 'ASBP' starting February 20, 2025. The transaction raised approximately $3.8 million through PowerUp's trust account and PIPE financing.
Aspire focuses on developing breakthrough innovations in FDA-approved drugs using its proprietary sublingual delivery system. Their pipeline includes a fast-acting aspirin product for cardiology emergencies, a Viagra/Cialis combination, and various bi-hormonal drugs. The company's patented technology enables rapid absorption of drugs directly into the bloodstream, bypassing the gastrointestinal tract and liver.
Led by CEO Kraig Higginson, Aspire plans to use the proceeds to accelerate development of its product pipeline and advance clinical trials, particularly for its lead product - an 'instant absorption' aspirin formulation.
Aspire Biopharma and PowerUp Acquisition Corp. (Nasdaq: PWUP) have completed their previously announced business combination, which was approved by PowerUp stockholders on January 31, 2025, and closed on February 17, 2025. Starting February 20, 2025, Aspire Biopharma will trade on the Nasdaq Global Market under the ticker symbols 'ASBP' (common stock) and 'ASBPW' (warrants).
The merger is expected to enhance Aspire's access to capital, enabling the company to expand its product development, accelerate strategic partnerships, and advance its fast-absorbing aspirin product for cardiac incidents, which management believes could receive FDA fast-track approval.
Aspire Biopharma and PowerUp Acquisition Corp (Nasdaq: PWUP) have announced a business combination agreement to create a Nasdaq-listed biopharmaceutical company. The transaction values Aspire at approximately $316 million pre-money equity value. Aspire focuses on developing products using novel delivery mechanisms to enhance the efficacy of FDA-approved drugs, nutraceuticals, and supplements.
The combined company, expected to be named Aspire Biopharma Holdings, Inc., plans to list on Nasdaq under the ticker symbol 'ASPH'. The merger is anticipated to complete by Q4 2024 or early Q1 2025. Aspire's lead product, Instaprin™, is a fast-acting, pH-neutral aspirin formulation targeting cardiology emergencies and pain management. The company plans to file a 505(b)(2) New Drug Application with the FDA for Instaprin™.
Aspire Biopharma, a developer of disruptive drug delivery technology, and PowerUp Acquisition Corp. (Nasdaq: PWUP) have signed a non-binding letter of intent for a potential business combination. The combined public company would be listed on a national securities exchange. Aspire, founded in 2021, focuses on novel delivery mechanisms for FDA-approved drugs, nutraceuticals, and supplements.
Aspire's lead product, Instaprin™, is a fast-acting, pH-neutral aspirin formulation addressing cardiology emergencies and pain management. The company plans to file a 505(b)(2) New Drug Application with the FDA. Aspire's pipeline includes various pharmaceutical and nutraceutical applications, such as a Viagra/Cialis combination and treatments for traumatic brain injury.
The proposed business combination aims to increase Aspire's market visibility and access to capital for product development. Both companies are working towards finalizing a definitive agreement, subject to various conditions and regulatory approvals.
PowerUp Acquisition Corp. (Nasdaq: PWUP) announced that on June 3, 2024, it received a notice from Nasdaq regarding non-compliance with the timely filing of its Quarterly Report on Form 10-Q for the period ending March 31, 2024. The company was required to submit a compliance plan by August 2, 2024. However, on June 5, 2024, PowerUp filed the delayed report with the SEC and believes it has regained compliance with Nasdaq's listing requirements.
PowerUp Acquisition Corp. (Nasdaq: PWUP) has rescheduled its extraordinary general meeting of shareholders to 2:00 p.m. Eastern Time on May 22, 2024. Originally slated for May 17, 2024, and later moved to May 21, 2024, this further postponement aims to allow shareholders to vote on extending the deadline for completing a business combination from May 23, 2024, to February 17, 2025. All other details of the meeting remain unchanged. Shareholders have until 5:00 p.m. Eastern Time on May 20, 2024, to submit their shares for redemption. For assistance, shareholders can reach out to Issuer Direct
PowerUp Acquisition Corp. (Nasdaq: PWUP) has postponed its extraordinary general meeting of shareholders from May 17, 2024, to May 21, 2024, at 9:00 a.m. Eastern Time. The meeting will ask shareholders to vote on extending the deadline to complete an initial business combination from May 23, 2024, to February 17, 2025. The location, record date, and purpose of the meeting remain unchanged. Shareholders now have until 5:00 p.m. Eastern Time on May 17, 2024, to submit their shares for redemption and may withdraw previously submitted requests by contacting the transfer agent.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of PowerUp Acquisition (PWUP)?
What is the market cap of PowerUp Acquisition (PWUP)?
